Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  celecoxib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 79 for your search:
Start Over
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Phase: Phase III, Phase II
Type: Prevention
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: RUN 2008-4198, ABR nr.: NL23569.091.08, CMO: 2008/148, EudraCT: 2008-003696-43, NCT00808743
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40015, NCT00064181
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SLCSG0501, NCT00300729
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EQ4-00-02-018, A3191107, NCT00141193
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000662707, CALGB-30801, NCT01041781
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 3c-03-19, NCT00159484
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NP01/07/03, NCT00212108
Celebrex With Preoperative Chemoradiation - Rectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 02-0130-C, Ontario Cancer ResearchNetwork, NCT00188565
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000490047, CHUV-CEPO-161-05, EU-20627, NCT00357617
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Phase: Phase II, Phase I
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB00024922, NCT00314262
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Other
Protocol IDs: F020703003, Link No: 000276825, NCT00581971
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 02I6, NCT00057980
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 01L2, PHARMACIA-NU-01L2, NCT00073866
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00730, 2009-0804, N01CN35159, NCT01021215
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000257584, DFCI-01278, NCI-G02-2117, CELGENE-2001-P-001757/3, NCT00047281
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000257587, DFCI-00302, NCI-G02-2118, CELGENE-2000-P-002521/1, NCT00047294
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000258562, DFCI-02024, DFCI-2002-P-00150/2, NCT00052611
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
Phase: Phase II
Type: Prevention
Status: Completed
Age: 45 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000271912, U01CA096134, P30CA016042, UCLA-0108074, NCT00055978
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 50 and under (at diagnosis)
Sponsor: NCI, Other
Protocol IDs: AEWS02P1, CDR0000302409, COG-AEWS02P1, NCT00061893
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0239, OSU-2003C0003, NCT00061906
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02720, LUNG 2002-01, NCI-5416, CDR0000304495, RUSH-LUNG-2001-1, 5416, NCT00062101
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000304540, P30CA016042, UCLA-0208074, NYH-CMC-0902-464, PHARMACIA-COXAON-0509-106, NCT00062179
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2003-0288, P30CA016672, MDA-2003-0288, NCI-6167, CDR0000322827, 6167, NCT00068432
Start Over